Treatment timing
Assessment, sampling, manufacture, admission and follow-up are separate stages. Obtain the centre’s plan before arranging travel; a technology name does not establish a fixed duration.
All oncology programmes
Blood-cell transplantation and MST
Haematopoietic stem-cell transplantation
Patient-derived or donor blood stem cells restore blood formation. Haematology and transplant teams plan treatment and recovery.
HSCT
- Technology basis
- Blood-forming stem cells
- Samples and tests
- Patient or donor source
- Key feature
- Haematology and transplantation
Overview
Blood-forming stem cells produce new blood cells. Transplantation can restore blood formation after conditioning; donor immune cells in an allogeneic transplant may also act against cancer. Care includes conditioning, infusion, recovery and long-term follow-up.
How it works
- 01
Choose the type
Autologous transplants use the patient’s cells; allogeneic transplants use donor cells and require matching assessment.
- 02
Condition and infuse
The team delivers conditioning followed by intravenous blood stem-cell infusion.
- 03
Restore blood formation
Monitor new blood-cell production, infection risks and immune recovery.
This illustrates the mechanism. Antigen-specific immune responses do not establish clinical benefit, which requires separate evidence.
Technology approach
Care commonly includes disease review, cell collection or donor preparation, conditioning, intravenous infusion and recovery care. Infusion is not a surgical replacement of bone marrow; inpatient and post-discharge recovery are integral.
Samples and manufacturing process
This outlines the main technical stages. Sampling, manufacturing and quality-testing time vary with the protocol and samples.
- 01
Transplant review
Determine the need, type and timing.
- 02
Cell and donor preparation
Collect autologous cells or arrange donor selection, matching and collection.
- 03
Conditioning and transplant
Provide inpatient conditioning, infusion and supportive care.
- 04
Engraftment and recovery
Observe blood recovery and plan infection, immune and disease follow-up.
Samples and assessment considerations
- Disease type, treatment response and transplant timing.
- Autologous collection feasibility or donor availability and HLA matching.
- Organ function, infections, other conditions, caregiver support and long-term follow-up.
Monitoring and follow-up
Monitoring after treatment
Blood-count recovery does not mean complete immune recovery. Continue reviews and follow the team’s instructions for medicines, infection precautions and travel.
Risks to discuss
Risks include infection, bleeding, organ injury, infertility and other short- or long-term complications. Allogeneic transplantation also requires attention to graft-versus-host disease; risks differ by transplant type.
During treatment, severe symptoms such as high fever, breathing difficulty or altered awareness require immediate contact with the medical team or local emergency services. Do not wait for an enquiry email response.
Records for assessment
Start with a diagnosis summary and a list of existing reports. Send full records through the agreed private channel. Clinicians decide whether missing tests are necessary; do not arrange every test independently.
- Pathology reports and available specimen details
- Previous regimens, dates and responses
- Recent imaging reports and available image files
- Existing molecular, target or HLA tests
- Other conditions, current medicines and allergies
- Preferred timing, caregiver and return-travel plans
Timing, travel and costs
Cost components
Review tests, manufacture or medicines, admission, supportive care and follow-up separately. Study cost coverage depends on its documents; confirm insurance in writing. Formal centre and service quotations govern charges.
Follow-up at home
Before leaving, confirm reviews, emergency contacts and coordination with local clinicians. Travel plans cannot replace decisions about admission or nearby observation.
Common questions
How do autologous and allogeneic transplants differ?
They use different cell sources and treatment rationales. Donor transplants require matching and assessment of additional immune risks.
Can I travel home as soon as blood counts recover?
Blood counts alone are insufficient. The team reviews infection risk, medicines, local follow-up and emergency arrangements before travel.
Related programmes
MST
Microtransplantation (MST)
Explore the programmeCAR-TCAR-T cell therapy
Explore the programmeTILTIL: tumour-infiltrating lymphocytes
Explore the programmeProgramme enquiries and records
HuaCure helps organise existing records, clarify programme requirements and coordinate specialist enquiries. Explore the technology, then discuss your circumstances with the medical team.
This website provides information, not medical advice. Healthcare providers assess diagnosis, treatment suitability, risks and research eligibility. HuaCure coordinates care and does not guarantee outcomes or study enrolment.
Compiled from programme technical materials and public medical sources to explain mechanisms and processes. It is not an individual medical recommendation or a promise of benefit.
Sources
Public information checked: 7 October 2026